{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:01:14Z","timestamp":1775804474473,"version":"3.50.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Omalizumab effectively improves quality of life in patients with moderate-to-severe perennial allergic rhinitis (PAR) uncontrolled by conventional medications. However, the duration of its efficacy remains unclear, and there is a lack of effective tools for individualized prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to identify predictors of Omalizumab duration of efficacy in moderate-to-severe PAR patients, then develop and validate an interpretable, machine learning-based predictive model to forecast the duration of efficacy following treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicenter retrospective study included 561 patients with moderate-to-severe PAR treated with Omalizumab at three clinical institutions. The trial was registered at Chinese Clinical Trial Registry, ChiCTR2500112034. Patient characteristics included age, sex, serum total IgE concentration, serum specific IgE (sIgE) concentrations including\n                      <jats:italic>Dermatophagoides pteronyssinus<\/jats:italic>\n                      (D1) and\n                      <jats:italic>Dermatophagoides farina<\/jats:italic>\n                      (D2), comorbid conditions (asthma, urticaria, conjunctivitis, atopic dermatitis), and injection frequency. Univariate and multivariate Cox regression were employed to investigate independent predictors of Omalizumab efficacy, with restricted cubic splines for dose-response analysis. Five survival machine learning models (CPH, XGBoost, RSF, SSVM, CoxBoost) were constructed and compared by comprehensive metrics. The optimal model was interpreted using the SHapley Additive exPlanations (SHAP) and deployed as an online web application.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Univariate Cox regression identified age, D1, D2, asthma and injection frequency as independent factors affecting Omalizumab efficacy duration. Multivariate analysis did not confirm D2 as significant. Dose-response analysis demonstrated enhanced protective effects beyond four injections. Among the five models, RSF demonstrated robust predictive performance. SHAP analysis identified injection frequency, age, D1, D2, and coexisting asthma as the most critical factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study developed and validated a machine learning-based model capable of forecasting the duration of Omalizumab efficacy in moderate-to-severe PAR based on readily available clinical variables.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2026.1784032","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:06:08Z","timestamp":1775801168000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward personalized prediction: a multicenter machine learning model for omalizumab response duration in moderate-to-severe perennial allergic rhinitis"],"prefix":"10.3389","volume":"7","author":[{"given":"Ziqi","family":"Miao","sequence":"first","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Allergology, Zhongnan Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuchen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Allergology, Zhongnan Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongfei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Allergy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jaci.2020.07.007","article-title":"Rhinitis 2020: a practice parameter update","volume":"146","author":"Dykewicz","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"70216","DOI":"10.1111\/all.70216","article-title":"Prevalence of allergic rhinitis in China continues to increase without reaching a plateau: an analysis of three waves of national surveys from 2005 to 2019","author":"Pu","year":"2026","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/14737167.2020.1819793","article-title":"Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy","volume":"20","author":"Dierick","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.anai.2010.10.014","article-title":"The economic impact of allergic rhinitis and current guidelines for treatment","volume":"106","author":"Meltzer","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1217388","DOI":"10.3389\/falgy.2023.1217388","article-title":"Mechanism and clinical evidence of immunotherapy in allergic rhinitis","volume":"4","author":"De Carli","year":"2023","journal-title":"Front Allergy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41392-023-01344-4","article-title":"Pathogenesis of allergic diseases and implications for therapeutic interventions","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/alr.23090","article-title":"International consensus statement on allergy and rhinology: allergic rhinitis\u20142023","volume":"13","author":"Wise","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11581","DOI":"10.1038\/srep11581","article-title":"Structural and physical basis for anti-IgE therapy","volume":"5","author":"Wright","year":"2015","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"9975","DOI":"10.1074\/jbc.M117.776476","article-title":"Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab","volume":"292","author":"Davies","year":"2017","journal-title":"J Biol Chem"},{"key":"B10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/1945892419884774","article-title":"Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials","volume":"34","author":"Yu","year":"2020","journal-title":"Am J Rhinol Allergy"},{"key":"B11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13223-025-00995-y","article-title":"Efficacy of omalizumab against Japanese cedar pollinosis in clinical practice","volume":"21","author":"Takeda","year":"2025","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4193\/Rhin24.105","article-title":"Omalizumab reduces allergic rhinitis symptoms due to Japanese cedar pollen by improving eosinophilic inflammation","volume":"63","author":"Hirano","year":"2025","journal-title":"Rhinology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.4193\/Rhin21.159","article-title":"Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis","volume":"59","author":"Tsabouri","year":"2021","journal-title":"Rhinology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.3390\/ijms26104509","article-title":"Recent studies and prospects of biologics in allergic rhinitis treatment","volume":"26","author":"Cheng","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria","volume":"76","author":"Fok","year":"2021","journal-title":"Allergy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/all.13345","article-title":"The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change","volume":"73","author":"Ertas","year":"2018","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1016\/j.jaip.2023.05.033","article-title":"Association between serum total IgE levels and clinical response to omalizumab for chronic spontaneous Urticaria: a systematic review and meta-analysis","volume":"11","author":"Chuang","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/pharmaceutics15020523","article-title":"Impact of omalizumab in patients with severe uncontrolled asthma and possible predictive biomarkers of response: a real-life study","volume":"15","author":"Rojo-Tolosa","year":"2023","journal-title":"Pharmaceutics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"17534666231170821","DOI":"10.1177\/17534666231170821","article-title":"Role of clinical biomarkers in predicting the effectiveness of omalizumab","volume":"17","author":"Zhang","year":"2023","journal-title":"Ther Adv Respir Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/17476348.2022.2092100","article-title":"Predictive biomarkers for response to omalizumab in patients with severe allergic asthma: a meta-analysis","volume":"16","author":"Li","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.rmed.2017.12.002","article-title":"Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics\u2019 responsiveness to omalizumab","volume":"134","author":"Suzukawa","year":"2018","journal-title":"Respir Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"110623","DOI":"10.1016\/j.intimp.2023.110623","article-title":"The ratio of total IgE level at week 16 to baseline significantly correlated with the clinical response to omalizumab in moderate to severe allergic rhinitis patients","volume":"122","author":"Zhao","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1101\/2023.09.29.23296326","article-title":"Machine Learning-Based Prediction of Free IgE Concentration in Allergic Rhinitis Patients Treated with Allergen Immunotherapy and Omalizumab","author":"Olanrewaju","year":""},{"key":"B24","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1016\/j.jaip.2022.07.020","article-title":"The allergic rhinitis and its impact on asthma (ARIA) approach of value-added medicines: as-needed treatment in allergic rhinitis","volume":"10","author":"Bousquet","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B25","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/j.1365-2222.2011.03734.x","article-title":"Validation of a self-questionnaire for assessing the control of allergic rhinitis","volume":"41","author":"Demoly","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA Expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1365-2222.2009.03381.x","article-title":"The minimal clinically important difference in allergic rhinitis","volume":"40","author":"Barnes","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/all.15207","article-title":"Determining the minimal important differences in the RQLQ score with grass and tree allergy immunotherapy versus placebo in adults with moderate-to-severe allergy","volume":"77","author":"Blaiss","year":"2022","journal-title":"Allergy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1111\/all.16654","article-title":"The minimal clinically important difference in allergen immunotherapy: an evidence-based approach","volume":"80","author":"Pfaar","year":"2025","journal-title":"Allergy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"103286","DOI":"10.1016\/j.eclinm.2025.103286","article-title":"Identification and validation of an explainable early-stage chronic kidney disease prediction model: a multicenter retrospective study","volume":"84","author":"He","year":"2025","journal-title":"eClinicalMedicine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"103001","DOI":"10.1016\/j.eclinm.2024.103001","article-title":"Development and validation of a machine learning-based model to predict survival in patients with cirrhosis after transjugular intrahepatic portosystemic shunt","volume":"79","author":"Da","year":"2025","journal-title":"eClinicalMedicine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jacc.2024.05.072","article-title":"Predicting long-term clinical outcomes of patients with recurrent pericarditis","volume":"84","author":"Yesilyaprak","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.cardfail.2022.02.012","article-title":"Predicting long-term mortality in patients with acute heart failure by using machine learning","volume":"28","author":"Park","year":"2022","journal-title":"J Card Fail"},{"key":"B34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40537-024-00905-w","article-title":"Feature selection strategies: a comparative analysis of SHAP-value and importance-based methods","volume":"11","author":"Wang","year":"2024","journal-title":"J Big Data"},{"key":"B35","doi-asserted-by":"publisher","first-page":"m441","DOI":"10.1136\/bmj.m441","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"Br Med J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/JAA.S288952","article-title":"Effectiveness and response predictors of omalizumab in treating patients with seasonal allergic rhinitis: a real-world study","volume":"14","author":"Ma","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B37","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1214\/08-AOAS169","article-title":"Random survival forests","volume":"2","author":"Ishwaran","year":"2008","journal-title":"Ann Appl Stat"},{"key":"B38","doi-asserted-by":"publisher","first-page":"62","DOI":"10.18502\/jbe.v6i1.4760","article-title":"Review of random survival forest method","volume":"6","author":"Rezaei","year":"2020","journal-title":"J Biostat Epidemiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12877-024-05154-3","article-title":"Development of machine learning models for patients in the high intrahepatic cholangiocarcinoma incidence age group","volume":"24","author":"Shen","year":"2024","journal-title":"BMC Geriatr"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.62347\/OJTY4008","article-title":"Development and validation of a random survival forest model for predicting long-term survival of early-stage young breast cancer patients based on the SEER database and an external validation cohort","volume":"14","author":"Li","year":"2024","journal-title":"Am J Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1186\/s12885-024-13190-w","article-title":"Artificial intelligence-based personalized survival prediction using clinical and radiomics features in patients with advanced non-small cell lung cancer","volume":"24","author":"Koyama","year":"2024","journal-title":"BMC Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"134075","DOI":"10.1016\/j.ijcard.2025.134075","article-title":"Developing explainable machine learning models from biochemical and clinical data to predict all-cause and cause-specific mortality in CVD-cancer comorbidity: a longitudinal study based on NHANES","volume":"446","author":"Chai","year":"2025","journal-title":"Int J Cardiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"24269","DOI":"10.1038\/s41598-025-05824-1","article-title":"Competing risk and random survival forest models for predicting survival in post-resection elderly stage I\u2013III colorectal cancer patients","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.3390\/cancers17233820","article-title":"Development and external validation of integrated machine learning-based prognostic model in oropharyngeal head and neck cancer using the systemic inflammatory response index","volume":"17","author":"Singh","year":"2025","journal-title":"Cancers"},{"key":"B45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/1471-2288-14-137","article-title":"Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints","volume":"14","author":"Van Der Ploeg","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/imj.13166","article-title":"Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair registry","volume":"46","author":"Gibson","year":"2016","journal-title":"Intern Med J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1016\/j.jaip.2023.07.030","article-title":"Age and fast initial response predict omalizumab retreatment in chronic urticaria","volume":"11","author":"Meertens","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B48","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/ajd.13656","article-title":"Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: real-life data","volume":"62","author":"Salman","year":"2021","journal-title":"Australas J Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e15248","DOI":"10.1111\/dth.15248","article-title":"Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria","volume":"35","author":"Foti","year":"2022","journal-title":"Dermatol Ther"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1016\/j.jaip.2020.03.051","article-title":"Aeroallergen sensitization, serum IgE, and eosinophilia as predictors of response to omalizumab therapy during the fall season among children with persistent asthma","volume":"8","author":"Sheehan","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B51","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ad.2024.08.014","article-title":"Redefining omalizumab discontinuation in chronic spontaneous Urticaria: the value of optimization and predictive factors of relapse. A 52-week multicenter study","volume":"116","author":"Ceravalls","year":"2025","journal-title":"Actas Dermosifiliogr"},{"key":"B52","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/jdv.15350","article-title":"Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients","volume":"33","author":"Marzano","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.jaci.2017.08.007","article-title":"Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria","volume":"140","author":"Ertas","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1159\/000525723","article-title":"Discontinuing omalizumab treatment in super-responder patients with allergic severe asthma: can the baseline total IgE level be used as a biological marker to decide discontinuing omalizumab treatment?","volume":"183","author":"Arslan","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1016\/j.csda.2009.04.009","article-title":"Estimating classification error rate: repeated cross-validation, repeated hold-out and bootstrap","volume":"53","author":"Kim","year":"2009","journal-title":"Comput Stat Data Anal"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e048008","DOI":"10.1136\/bmjopen-2020-048008","article-title":"Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence","volume":"11","author":"Collins","year":"2021","journal-title":"BMJ Open"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1784032\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:06:09Z","timestamp":1775801169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1784032\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":56,"alternative-id":["10.3389\/falgy.2026.1784032"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1784032","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1784032"}}